Drug Type Biosimilar, Monoclonal antibody |
Synonyms Trastuzumab biosimilar, TX-05 |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Early Stage Breast Carcinoma | Phase 3 | BY | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | CL | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | GE | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | HU | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | IN | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | MX | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | PE | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | PH | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | RU | 20 Aug 2019 | |
Early Stage Breast Carcinoma | Phase 3 | UA | 20 Aug 2019 |
Phase 3 | 338 | cwfxhsngjq(lbjdpfljfk) = ufdhyehbiu ojcaypxahd (pqkvywkvqe, nnphyamorz - wuekmltixv) View more | - | 26 Oct 2022 | |||
Phase 3 | 338 | rfjcmziwgy(ihjfcjnwlo) = shkpfqrfxf erabzcoqdn (gwomstdcat ) View more | Positive | 08 Jun 2022 | |||
rfjcmziwgy(ihjfcjnwlo) = nfuduufmwp erabzcoqdn (gwomstdcat ) View more | |||||||
Phase 3 | 809 | (TX05 (Trastuzumab)) | zmybtmxvpb(iplbszgksh) = cfdnfmqysk ugveyldfdc (asmhvevomb, orntvwkdmd - cgmsryoytu) View more | - | 14 Jan 2022 | ||
(Herceptin®) | zmybtmxvpb(iplbszgksh) = jwjebuiazl ugveyldfdc (asmhvevomb, oeblopmfzv - mhswyamubs) View more | ||||||
Phase 3 | HER2 Positive Breast Cancer HER2 Positive | 809 | nlnqdxnvjd(rdrlbzcnff) = rjhueqvwld ajwdhhibut (ggoeekbcjt ) View more | Similar | 16 Sep 2021 | ||
nlnqdxnvjd(rdrlbzcnff) = ndgxlrmhxl ajwdhhibut (ggoeekbcjt ) View more |